首页> 外文期刊>Expert opinion on pharmacotherapy >Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease.
【24h】

Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease.

机译:慢性阻塞性肺病中吸烟干预的振伤线。

获取原文
获取原文并翻译 | 示例
       

摘要

INTRODUCTION: In smoking-related chronic obstructive pulmonary disease (COPD), smoking cessation was previously demonstrated to reduce lung function decline and disease morbidity if it resulted in a sustained tobacco abstinence. Varenicline is a newer pharmacologic therapeutic agent able to reduce withdrawal symptoms in smokers, and this makes it particularly valuable in inducing abstinence in patients with significant addiction. AREAS COVERED: This paper discusses the results of a randomized, placebo-controlled study evaluating the effects of a smoking cessation intervention including varenicline in patients with COPD. EXPERT OPINION: Varenicline can be an appropriate aid to maintaining smoking abstinence in patients with COPD and heavier nicotine addiction, and the documentation of the long-term effects of a smoking cessation intervention that includes this pharmacologic therapeutic agent is necessary.
机译:None

著录项

  • 来源
    《Expert opinion on pharmacotherapy》 |2011年第16期|共3页
  • 作者

    Antoniu SA; Trofor AC;

  • 作者单位

    University of Medicine and Pharmacy Gr.T.Popa Iasi Pulmonary Disease University Hospital;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

  • 入库时间 2022-08-20 18:08:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号